Literature DB >> 11857080

Direct integrin alphavbeta6-ERK binding: implications for tumour growth.

Nuzhat Ahmed1, Jun Niu, Douglas J Dorahy, Xinhua Gu, Sarah Andrews, Cliff J Meldrum, Rodney J Scott, Mark S Baker, Ian G Macreadie, Michael V Agrez.   

Abstract

Blockade of the mitogen-activated protein (MAP) kinase pathway suppresses growth of colon cancer in vivo. Here we demonstrate a direct link between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion molecule, integrin alphavbeta6, in colon cancer cells. Down-regulation of beta6 integrin subunit expression inhibits tumour growth in vivo and MAP kinase activity in response to serum stimulation. In alphavbeta6-expressing cells ERK2 is bound only to the beta6 subunit. The increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all accounted for by beta6-bound ERK. Deletion of the ERK2 binding site on the beta6 cytoplasmic domain inhibits tumour growth and leads to an association between ERK and the beta5 subunit. The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857080     DOI: 10.1038/sj.onc.1205286

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Structural and mechanical functions of integrins.

Authors:  Luke R Anderson; Thomas W Owens; Matthew J Naylor
Journal:  Biophys Rev       Date:  2013-10-08

2.  Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.

Authors:  Nuzhat Ahmed; Clyde Riley; Greg Rice; Michael Quinn
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy.

Authors:  Liu Enyu; Niu Zhengchuan; Wang Jiayong; Liang Benjia; Sun Qi; Qin Ruixi; Peng Cheng; Abdul Qadir Khan; Song Wei; Niu Jun
Journal:  Tumour Biol       Date:  2015-05-17

Review 4.  Defining the role of integrin alphavbeta6 in cancer.

Authors:  A Bandyopadhyay; S Raghavan
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

5.  Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.

Authors:  Francesca Sacco; Michele Tinti; Anita Palma; Emanuela Ferrari; Aurelio P Nardozza; Rob Hooft van Huijsduijnen; Takamune Takahashi; Luisa Castagnoli; Gianni Cesareni
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

6.  PKD1/PKCmu promotes alphavbeta3 integrin recycling and delivery to nascent focal adhesions.

Authors:  Alison J Woods; Dominic P White; Patrick T Caswell; Jim C Norman
Journal:  EMBO J       Date:  2004-06-10       Impact factor: 11.598

7.  Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression.

Authors:  Eleonora Patsenker; Yury Popov; Felix Stickel; Alfred Jonczyk; Simon L Goodman; Detlef Schuppan
Journal:  Gastroenterology       Date:  2008-04-16       Impact factor: 22.682

8.  Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Zequn Li; Pengfei Lin; Chao Gao; Cheng Peng; Song Liu; Huijie Gao; Ben Wang; Jiayong Wang; Jun Niu; Weibo Niu
Journal:  Tumour Biol       Date:  2015-11-07

9.  Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer.

Authors:  Pei-Long Lian; Zhao Liu; Guang-Yun Yang; Rui Zhao; Zhao-Yang Zhang; Yue-Guang Chen; Zhuo-Nan Zhuang; Ke-Sen Xu
Journal:  World J Gastroenterol       Date:  2016-04-14       Impact factor: 5.742

10.  Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro.

Authors:  Sonali Sonnylal; Shiwen Xu; Helen Jones; Angela Tam; Vivek R Sreeram; Markella Ponticos; Jill Norman; Pankaj Agrawal; David Abraham; Benoit de Crombrugghe
Journal:  J Cell Sci       Date:  2013-03-22       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.